One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
ImageneBio, Inc.
IMA · NCM · Healthcare · Biotechnology
Current price
$4.20
52-week range
$3.88 - $9.10
Market cap
$47.77M
Balance sheet
Healthy
-23.81x Concerning
Net cash $134.24M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
ImageneBio, Inc.
ImageneBio, Inc. is a company working on new medicines for diseases where the body's own immune system attacks itself or causes too much inflammation, like autoimmune conditions. Their main focus is a drug candidate called IMG-007, which is currently being tested in people. The money ImageneBio makes will eventually come from selling these approved medicines, which matters because it's how they can continue researching and developing treatments to help patients.
How the company got here
ImageneBio, Inc., formerly known as Ikena Oncology, Inc., is a company focused on developing new medicines. It officially changed its name to ImageneBio in July 2025, signaling a potential shift or expansion in its focus. The company is currently in the 'clinical-stage,' meaning its main drug candidates are being tested in human trials, not yet available for widespread use. This stage is crucial for determining if a new drug is safe and effective.
What it actually does
ImageneBio is a biopharmaceutical company, which means it researches and develops drugs, specifically for diseases related to the immune system. These are conditions where the body's defense system either attacks itself (autoimmune diseases) or causes harmful inflammation. The company's goal is to create treatments that can help patients suffering from these challenging conditions.
Business Lines
ImageneBio currently operates with a primary focus on developing a single, promising drug candidate. This means the company's efforts and resources are concentrated on advancing this one potential treatment through the necessary stages of testing and approval. While it's a single-product focus now, the success of this candidate will determine the company's future growth and potential for additional product lines.
IMG-007: The Lead Product Candidate
The company's main focus is a drug candidate called IMG-007. This is a type of therapy known as a 'monoclonal antibody,' which is a lab-made protein designed to target specific parts of the body's immune system. Specifically, IMG-007 targets a receptor called OX40, which is found on certain immune cells called T cells when they are activated. By blocking the interaction of this receptor, the drug aims to reduce harmful immune responses that cause disease.
What management is betting on now
ImageneBio's current strategy hinges on successfully navigating the clinical trials for IMG-007. The company is in Phase 1b/2a trials, which are designed to assess the drug's safety, determine the right dosage, and get an early look at its effectiveness in patients. Positive results in these trials are critical for attracting further investment and moving towards potential regulatory approval and commercialization of the drug.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-10.18M
Diluted EPS
-0.63
Operating cash flow
$-9.07M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-10.62M
Diluted EPS
-0.95
Operating cash flow
$-14.80M
Free cash flow
—
Fetching…
Sources
Revenue
$0.00
Net income
$-9.18M
Diluted EPS
-6.49
Operating cash flow
$-7.22M
Free cash flow
—
Fetching…
Sources
Revenue
$0.00
Net income
$-24.78M
Diluted EPS
-2.91
Operating cash flow
$-26.64M
Free cash flow
—
Fetching…
Sources
Revenue
$0.00
Net income
$-2.77M
Diluted EPS
-0.06
Operating cash flow
$-3.42M
Free cash flow
—
Fetching…
Sources
Revenue
$800.00K
Net income
$-8.62M
Diluted EPS
-0.18
Operating cash flow
$-10.56M
Free cash flow
—
Fetching…
Sources
Revenue
$3.50M
Net income
$-9.12M
Diluted EPS
-0.20
Operating cash flow
$-6.26M
Free cash flow
—
Fetching…
Sources
Revenue
$3.50M
Net income
$-10.23M
Diluted EPS
-0.21
Operating cash flow
$-8.94M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $4.20
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $134.2M - more cash than debt. Interest coverage -23.8x.
Net debt
$-134.24M
Interest coverage
-23.81x
ImageneBio, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
IMA
BASELINE
ImageneBio, Inc.
Total debt $1.91M Interest coverage -23.81x This is the baseline the peer rows are being compared against.
Total debt $28.10M Interest coverage -36.67x Neither company has much profit cushion over interest right now.
Total debt $1.27M Interest coverage -1,378.55x Neither company has much profit cushion over interest right now.
Total debt $2.75M Interest coverage -56.77x Neither company has much profit cushion over interest right now.
Total debt $66.95M Interest coverage 36.18x This peer still has a real interest-payment cushion, while IMA does not.
What you should know
The case for and against IMA
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -82.7% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.97x
P/B
0.33x
P/S
—
EV/EBITDA
1.48x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-82.7%
ROA
-43.1%
Health
Liquidity and balance-sheet strength
Debt / equity
0.01x
Current ratio
21.47x
Quick ratio
20.71x
Total debt
$1.91M
Total cash
$136.15M
Growth
How the business has been compounding
Revenue TTM
$800.00K
Revenue 5Y CAGR
-59.9%
EPS TTM
-4.24
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-57.73M
Free CF TTM
$-46.42M
FCF margin
-5,802.2%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—